1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Dr. Lal PathLabs Limited

Dr. Lal PathLabs Limited

LALPATHLAB.BO
Dr. Lal PathLabs LimitedIN flagBombay Stock Exchange
1,684.25
INR
+32.85
- -
281.68BMarket Cap
Dr. Lal PathLabs Limited
LALPATHLAB.BO
(Bombay Stock Exchange)

Recent

price

1,684.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
14.35
20.7
27.33
33.76
61.01
48.16
56.12
64.52
73.09
80.73
95.78
126.22
121.68
133.95
147.74
- -
121.79
Revenue per Share
1.76
2.71
3.34
4.82
8.85
8.05
9.51
10.42
12.1
13.71
17.66
20.85
14.41
21.52
29.24
- -
21.23
Basic EPS, GAAP
1.07
2.84
4.14
3.94
8
6.96
7.36
7.61
10.72
12.4
20.51
-1.78
24.83
28.75
30.92
- -
- -
Free Cash Flow per Basic Share
0.9
0.58
0.91
0.58
0.96
0.95
2.29
1.94
3.35
9.44
6.03
7.06
6.22
12.1
12.44
- -
- -
Dividend per Share
3.13
4.67
7.06
13.47
26.92
23.71
30.27
40.27
48.72
52.95
64.48
78.14
86.52
99.88
116.67
- -
139.05
Book Value per Share
3.14
4.46
6.8
10.32
26.26
27.03
33.93
45.41
54.81
56.54
68.52
35.26
47.88
62.14
84.48
- -
107.9
Tangible Book Value per Share
165
165
165
165
108
164
163
164
165
165
165
165
166
166
167
- -
167
Basic Weighted Avg Shares
2,373
3,422
4,517
5,579
6,596
7,913
9,124
10,569
12,034
13,304
15,812
20,874
20,166
22,265
24,612
27,628
20,322
Sales/Revenue/Turnover
18.64
19.85
17.37
20.39
19.4
23.04
34.1
34.03
33.85
20.45
22.74
35.31
17.05
20.97
36.52
37.1
41.4
Operating Margin (%)
136
198
204
272
282
283
275
331
382
728
772
1,081
1,502
1,436
1,419
1,618
1,213
Depreciation Expense
291
447
551
796
957
1,322
1,546
1,707
1,992
2,259
2,916
3,448
2,388
3,577
4,871
5,048
3,542
Net Income, GAAP
33.95
32
30.62
32.67
30.98
33.62
34.3
34.26
33.3
26.7
24.83
26.24
29.88
28.32
21.21
23.81
23.19
Effective Tax Rate (%)
12.27
13.07
12.21
14.26
14.51
16.71
16.94
16.15
16.55
16.98
18.44
16.52
11.84
16.07
19.79
18.27
17.43
Profit Margin (%)
-199
-67
277
730
1,699
2,888
3,817
5,071
6,753
6,653
8,709
3,752
5,033
6,631
9,612
11,159
11,159
Working Capital
41
- -
- -
- -
- -
- -
- -
- -
- -
930
1,102
3,055
2,133
1,030
1,026
1,454
1,454
LT Debt
935
1,171
1,637
2,333
3,434
4,695
5,980
7,916
9,510
10,540
12,760
15,435
16,995
18,854
22,065
25,413
25,413
Total Equity
- -
40.09
38.48
38.35
30.57
29.87
38.63
34.37
31.48
18.91
20.98
31.42
11.66
15.94
31.73
30.83
25.52
Return on Invested Capital (%)
- -
61.16
55.73
45.94
36.71
38.34
34.73
29.41
26.98
25.73
26.34
23.28
14.03
19.54
24.5
22.07
15.56
Return on Capital (%)
- -
69.35
56.84
46.9
37.25
38.85
35.07
29.65
27.25
26.98
30.11
29.26
17.52
23.12
27.04
23.68
16.61
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
536
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
1,454
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
167
- -
167
Market Capitalization
259,570
247,302
219,244

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
- -
- -
15,665
Cash, Cash Equivalents & STI
- -
- -
13,307
Accounts Receivable, Net
- -
- -
1,107
Inventories
- -
- -
439
Total Current Liabilities
- -
- -
4,506
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
536
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.6%
14.84%
15.17%
Free Cash Flow
-146.27%
-318.91%
-10.25%
Net Income, GAAP
16.36%
15.42%
3.62%
Sales/Revenue/Turnover
13.62%
12.37%
12.25%
Total Cash Common Dividend
45.42%
22.26%
7.39%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,410
6,013
5,389
5,453
22,265
2025
6,019
6,602
5,967
6,024
24,612
2026
6,698
- -
6,598
7,026
27,628

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4.97
6.58
4.89
- -
21.52
2025
6.4
7.76
5.8
- -
29.24
2026
7.94
- -
5.42
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
12.1
2025
- -
- -
- -
- -
12.44
2026
- -
- -
- -
- -
- -
Similar Companies
MDxHealth S.A. (MXDHF)
H.U. Group Holdings, Inc. (4544.T)
CelLBxHealth plc (CLBX.L)
Medpace Holdings, Inc. (MEDP)
Thermo Fisher Scientific Inc. (0R0H.L)
Wellfully Limited (WFL.AX)
Business
Dr. Lal PathLabs Limited Dr Lal PathLabs Ltd (LALPATHLAB.BO) operates as one of India's leading integrated diagnostic service providers, offering a comprehensive portfolio of pathology, radiology, and cardiology tests through an extensive network of clinical laboratories, patient service centers, and pick-up points across the country. The company provides routine blood and urine tests; specialized diagnostics for viral, bacterial infections, thyroid, diabetes, liver, kidney, and cancer screenings; advanced genomic profiles, myeloid testing for hematological malignancies, and amyloid typing solutions; preventive health packages including SwasthFit; full body checkups; infectious disease panels for COVID-19, dengue, and tuberculosis; fertility assessments; autoimmune disorder tests; imaging services such as X-rays, MRIs, and CT scans; and corporate wellness programs encompassing drug tests, pre-employment checkups, and onsite health screenings. Founded in 1949 by Dr. Major S. K. Lal and headquartered in Gurugram, Haryana, Dr. Lal PathLabs Limited maintains pan-India operations with over 298 clinical labs, 6,607 patient service centers, and satellite labs, serving individual patients, hospitals, healthcare providers, and corporates while holding NABL and international CAP accreditations. In recent developments, the company pursues major acquisitions in South India valued at up to INR 4,000 crore to bolster regional presence following the 2021 Suburban Diagnostics purchase; expands radiology and cardiology offerings; plans 20 new labs in cities like Bengaluru and Hyderabad via subsidiary Suburban Diagnostics India Pvt. Ltd.; and proposes a 1:1 bonus issue alongside RSU grants and capital increase as of November 2025.